Q2 Revenue and Earnings Report: Universal Health Services (UHS) Exceeds Consensus Estimates
ByAinvest
Wednesday, Jul 24, 2024 8:09 pm ET1min read
UHS--
According to a recent report by Zacks Investment Research, UHS reported an adjusted earnings per share (EPS) of $4.31 for the quarter, surpassing the consensus estimate of $3.37 by a substantial margin of 30.2% [1]. The company's revenue also came in at $3.91 billion, a 10.1% year-over-year (YoY) increase and above the consensus estimate of $3.85 billion [1].
Key metrics within UHS's behavioral and acute care hospital services sectors reflected this growth and outperformance, highlighting the company's commitment to excellence in patient care and operational efficiency [1]. However, despite these positive developments, UHS shares returned -1.3% over the past month, contrasting the Zacks S&P 500 composite's 1.8% increase during the same period [1].
While UHS's financial performance is noteworthy on its own, it is essential to contextualize it in comparison to a leading competitor, HCA Healthcare (HCA). HCA, another major player in the healthcare industry, reported a second-quarter 2024 adjusted EPS of $5.50, which beat the consensus estimate by 10.7% [2]. The company's revenue, at $17.5 billion, also showed a 10.3% YoY improvement and surpassed the consensus estimate [2].
Despite these similarities, there are differences between the two companies' performance. For example, HCA's same-facility equivalent admissions grew 5.2% YoY, compared to UHS's 5.6% [1][2]. However, UHS's same-facility emergency room visits experienced a more significant growth rate of 5.5% YoY, compared to HCA's 4.3% [1][2].
Moreover, HCA's salaries and benefits, supplies, and other operating expenses grew 8.9% YoY, compared to UHS's 8.9% [1][2]. This suggests that HCA may be facing similar cost pressures but is managing them slightly differently from UHS.
In conclusion, while both UHS and HCA reported strong second-quarter 2024 financial performances, UHS demonstrated more significant growth and outperformance in certain key metrics. As the healthcare industry continues to evolve, the financial reports of companies like UHS and HCA will provide valuable insights into their performance, growth prospects, and competitive positions.
[1] https://www.nasdaq.com/articles/universal-health-services-inc-uhs-beats-q2-earnings-ups-2024-eps-view
[2] https://www.nasdaq.com/articles/hca-healthcare-hca-beats-q2-earnings-ups-2024-eps-view
In Q2 2024, Universal Health Services (UHS) reported $3.91 billion in revenue, up 10.1% YoY, and EPS of $4.31, compared to $2.53 the previous year. The company's reported revenue surpassed the Zacks Consensus Estimate of $3.85 billion, with EPS outperforming expectations of $3.37. Key metrics for behavioral and acute care hospital services were also highlighted, reflecting growth and outperforming analyst estimates. UHS shares returned -1.3% in the past month, while the Zacks S&P 500 composite rose 1.8%.
In the rapidly evolving world of healthcare, quarterly financial reports serve as beacons of progress and performance for investors and industry observers alike. One such standout report comes from Universal Health Services (UHS), which in Q2 2024, demonstrated impressive growth and outperformance compared to analyst estimates.According to a recent report by Zacks Investment Research, UHS reported an adjusted earnings per share (EPS) of $4.31 for the quarter, surpassing the consensus estimate of $3.37 by a substantial margin of 30.2% [1]. The company's revenue also came in at $3.91 billion, a 10.1% year-over-year (YoY) increase and above the consensus estimate of $3.85 billion [1].
Key metrics within UHS's behavioral and acute care hospital services sectors reflected this growth and outperformance, highlighting the company's commitment to excellence in patient care and operational efficiency [1]. However, despite these positive developments, UHS shares returned -1.3% over the past month, contrasting the Zacks S&P 500 composite's 1.8% increase during the same period [1].
While UHS's financial performance is noteworthy on its own, it is essential to contextualize it in comparison to a leading competitor, HCA Healthcare (HCA). HCA, another major player in the healthcare industry, reported a second-quarter 2024 adjusted EPS of $5.50, which beat the consensus estimate by 10.7% [2]. The company's revenue, at $17.5 billion, also showed a 10.3% YoY improvement and surpassed the consensus estimate [2].
Despite these similarities, there are differences between the two companies' performance. For example, HCA's same-facility equivalent admissions grew 5.2% YoY, compared to UHS's 5.6% [1][2]. However, UHS's same-facility emergency room visits experienced a more significant growth rate of 5.5% YoY, compared to HCA's 4.3% [1][2].
Moreover, HCA's salaries and benefits, supplies, and other operating expenses grew 8.9% YoY, compared to UHS's 8.9% [1][2]. This suggests that HCA may be facing similar cost pressures but is managing them slightly differently from UHS.
In conclusion, while both UHS and HCA reported strong second-quarter 2024 financial performances, UHS demonstrated more significant growth and outperformance in certain key metrics. As the healthcare industry continues to evolve, the financial reports of companies like UHS and HCA will provide valuable insights into their performance, growth prospects, and competitive positions.
[1] https://www.nasdaq.com/articles/universal-health-services-inc-uhs-beats-q2-earnings-ups-2024-eps-view
[2] https://www.nasdaq.com/articles/hca-healthcare-hca-beats-q2-earnings-ups-2024-eps-view

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet